Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma Corporation, often referred to as MTPC, is a prominent player in the global pharmaceutical industry, headquartered in Japan. Established in 1678, the company has evolved significantly, focusing on innovative drug development and therapeutic solutions primarily in the fields of neurology, immunology, and diabetes care. With a strong presence in Japan, North America, and Europe, Mitsubishi Tanabe Pharma is renowned for its unique core products, including treatments for multiple sclerosis and other chronic conditions. The company has achieved notable milestones, such as the successful launch of its flagship drug, which has positioned it as a leader in the biopharmaceutical market. Committed to advancing healthcare, Mitsubishi Tanabe Pharma continues to make significant contributions to patient well-being through its research and development initiatives.
DitchCarbon Score
How does Mitsubishi Tanabe Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mitsubishi Tanabe Pharma's score of 52 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mitsubishi Tanabe Pharma's reported carbon emissions
In 2023, Mitsubishi Tanabe Pharma reported total greenhouse gas emissions of approximately 740,900,000 kg CO2e. This figure includes Scope 1 emissions of about 18,700,000 kg CO2e, Scope 2 emissions of around 36,300,000 kg CO2e, and significant Scope 3 emissions totalling approximately 700,900,000 kg CO2e. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (approximately 682,200,000 kg CO2e) and capital goods (about 17,100,000 kg CO2e). The company has set ambitious climate commitments, aiming for a 45% reduction in Scope 1 and Scope 2 emissions by 2030, compared to 2019 levels, with a long-term goal of achieving net-zero emissions by 2050. These targets encompass all domestic and overseas group companies and are part of a broader strategy to address climate change. Mitsubishi Tanabe Pharma's emissions data is cascaded from its parent company, Mitsubishi Tanabe Pharma Corporation, which provides a comprehensive overview of the organisation's climate impact and commitments. The company is actively working towards its reduction targets and has demonstrated progress in its sustainability initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 35,400,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 71,800,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mitsubishi Tanabe Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
